

FOR OFFICIAL USE ONLY

ACCESS DB #

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: MARK BERCH Examiner #: 59193 Date: 9/9/04
 Art Unit: 1624 Phone Number: 2-0663 Serial Number: 10719102
 Location (Bldg/Room#): 5C01 (Mailbox #): 5C18 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____




Inventors (please provide full names): _____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



CAS React B \rightarrow A
 Also: B, b's with A & B

RECEIVED
 SEP - 9 2005
 STIC/CH/CHEM DIVISION

CAS React
L6

KCAP
L24

STAFF USE ONLY

Type of Search

Vendors and cost where applicable

Searcher: _____

____ NA Sequence (#)

____ STN

____ Dialog

Searcher Phone #: _____

____ AA Sequence (#)

____ Questel/Orbit

____ Lexis/Nexis

Searcher Location: _____

____ Structure (#)

____ Westlaw

____ WWW/Internet

Date Searcher Picked Up: 9-14-5

____ Bibliographic

____ In-house sequence systems

Date Completed: _____

____ Litigation

____ Commercial

____ Oligomer

____ Score/Length

____ Interference

____ SPDI

____ Encode/Transl

Searcher Prep & Review Time: _____

____ Fulltext

____ Other (specify)

Online Time: _____

____ Other

=> d'his ful

(FILE 'HOME' ENTERED AT 10:56:36 ON 14 SEP 2005)

FILE 'REGISTRY' ENTERED AT 10:56:43 ON 14 SEP 2005

L1 STR

FILE 'CASREACT' ENTERED AT 11:05:42 ON 14 SEP 2005

L2 STR L1

L3 STR L2

L4 STR L1

L5 0 SEA SSS SAM L4 (0 REACTIONS)

L6 0 SEA SSS FUL L4 (0 REACTIONS)

L7 STR L1

FILE 'HCAPLUS' ENTERED AT 11:14:42 ON 14 SEP 2005

E US2003-719102/APPS

L8 2 SEA ABB=ON PLU=ON (US2003-719102/AP OR US2003-719102/PRN)
SEL RN

FILE 'REGISTRY' ENTERED AT 11:15:04 ON 14 SEP 2005

L9 94 SEA ABB=ON PLU=ON (105-56-6/BI OR 4637-24-5/BI OR 873-83-6/BI
OR 100-39-0/BI OR 102284-71-9/BI OR 107-08-4/BI OR 109-65-9/BI
OR 110472-90-7/BI OR 133657-31-5/BI OR 142665-13-2/BI OR
146830-67-3/BI OR 172751-17-6/BI OR 175205-61-5/BI OR 18162-48-
6/BI OR 2434-53-9/BI OR 26914-02-3/BI OR 3587-60-8/BI OR
37622-90-5/BI OR 401647-24-3/BI OR 41862-09-3/BI OR 41862-11-7/
BI OR 531506-20-4/BI OR 531506-21-5/BI OR 531506-22-6/BI OR
531506-23-7/BI OR 531506-24-8/BI OR 531506-25-9/BI OR 531506-26
-0/BI OR 531506-27-1/BI OR 531506-28-2/BI OR 531506-29-3/BI OR
531506-30-6/BI OR 531506-31-7/BI OR 531506-32-8/BI OR 531506-33
-9/BI OR 531506-34-0/BI OR 531506-35-1/BI OR 531506-36-2/BI OR
531506-37-3/BI OR 531506-38-4/BI OR 531506-39-5/BI OR 531506-40
-8/BI OR 531506-41-9/BI OR 531506-42-0/BI OR 531506-43-1/BI OR
531506-44-2/BI OR 531506-45-3/BI OR 531506-47-5/BI OR 531506-49
-7/BI OR 531506-50-0/BI OR 538-32-9/BI OR 542-69-8/BI OR
57238-75-2/BI OR 5770-23-0/BI OR 609-65-4/BI OR 625-52-5/BI OR
631913-91-2/BI OR 631913-92-3/BI OR 631913-93-4/BI OR 631913-94
-5/BI OR 631913-95-6/BI OR 631913-96-7/BI OR 631913-97-8/BI OR
631913-98-9/BI OR 631913-99-0/BI OR 631914-00-6/BI OR 631914-01
-7/BI OR 631914-02-8/BI OR 631914-03-9/BI OR 631914-04-0/BI OR
631914-05-1/BI OR 637-59-2/BI OR 63981-31-7/BI OR 71597-85-8/BI
OR 73217-31-9/BI OR 752222-78-9/BI OR 752222-79-0/BI OR
752222-81-4/BI OR 752222-82-5/BI OR 752222-83-6/BI OR 752222-84
-7/BI OR 752222-85-8/BI OR 752222-86-9/BI OR 752222-87-0/BI OR
752222-88-1/BI OR 76513-69-4/BI OR 80798-51-2/BI OR 80798-52-3/
BI OR 81250-30-8/BI OR 81250-31-9/BI OR 81250-34-2/BI OR
90154-04-4/BI OR 94781-76-7/BI OR 99-76-3/BI)

L10 68 SEA ABB=ON PLU=ON L9 AND NCNC3/ESS

L11 36 SEA ABB=ON PLU=ON L10 AND NR>3

L12 47 SEA ABB=ON PLU=ON L10 AND NR>2

FILE 'HCAPLUS' ENTERED AT 11:16:16 ON 14 SEP 2005

L13 2 SEA ABB=ON PLU=ON L12 AND L8
D IALL HITSTR 1-2

FILE 'CASREACT' ENTERED AT 11:17:01 ON 14 SEP 2005

E US2003-719102/APPS

FILE 'REGISTRY' ENTERED AT 11:17:52 ON 14 SEP 2005

D L7
L14 STR L1
L15 0 SEA SSS SAM L7
D QUE
L16 89 SEA SSS FUL L7
L17 0 SEA SSS SAM L14
L18 27 SEA SSS FUL L14

FILE 'HCAPLUS' ENTERED AT 11:22:13 ON 14 SEP 2005

L19 3 SEA ABB=ON PLU=ON L16 AND L18
L20 1 SEA ABB=ON PLU=ON L8 AND L19
L21 3 SEA ABB=ON PLU=ON L18 (L) RACT+ALL/RL
L22 21 SEA ABB=ON PLU=ON L16 (L) PREP+ALL/RL
L23 2 SEA ABB=ON PLU=ON L21 AND L22
L24 3 SEA ABB=ON PLU=ON L19 OR L23

FILE 'BEILSTEIN' ENTERED AT 11:26:22 ON 14 SEP 2005

D QUE
L25 6 SEA SSS FUL L7
L26 0 SEA SSS FUL L14
SEL L25 BRN
L27 0 SEA ABB=ON PLU=ON (1174144/PBRN OR 3578661/PBRN OR 6155823/PB
RN OR 6883344/PBRN OR 8287289/PBRN OR 8814448/PBRN)

FILE 'STNGUIDE' ENTERED AT 11:29:20 ON 14 SEP 2005

FILE 'BEILSTEIN' ENTERED AT 11:31:20 ON 14 SEP 2005

L28 8 SEA ABB=ON PLU=ON (1174144/RX.PBRN OR 3578661/RX.PBRN OR
6155823/RX.PBRN OR 6883344/RX.PBRN OR 8287289/RX.PBRN OR
8814448/RX.PBRN)

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 SEP 2005 HIGHEST RN 863091-33-2

DICTIONARY FILE UPDATES: 13 SEP 2005 HIGHEST RN 863091-33-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE CASREACT

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 11 Sep 2005 VOL 143 ISS 11

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
*****
*
*      CASREACT now has more than 9.2 million reactions
*
*****
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Sep 2005 VOL 143 ISS 12

FILE LAST UPDATED: 13 Sep 2005 (20050913/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BEILSTEIN

FILE RELOADED ON OCTOBER 20, 2002

FILE LAST UPDATED ON JUNE 29, 2005

FILE COVERS 1771 TO 2005.

FILE CONTAINS 9,271,550 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in

separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

 * PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
 * SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
 * ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
 * ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
 * FOR PRICE INFORMATION SEE HELP COST *

NEW

* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
 * NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE STNGUIDE


FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 9, 2005 (20050909/UP).


=> ~~query~~ stat 16

L4 STR


RRT



PRO



Hy~G2~G3
 @50 51 52



Cb~G2~G3
 @59 60 61

VAR G1=50/59
 REP G2=(0-10) C
 VAR G3=53/HY
 NODE ATTRIBUTES:

CONNECT IS E3 RC AT 2
 CONNECT IS E3 RC AT 3
 CONNECT IS E3 RC AT 4
 CONNECT IS E3 RC AT 6
 CONNECT IS E2 RC AT 7
 CONNECT IS E3 RC AT 8
 CONNECT IS E2 RC AT 9
 CONNECT IS E1 RC AT 10
 CONNECT IS E1 RC AT 11
 CONNECT IS E3 RC AT 14
 CONNECT IS E3 RC AT 15
 CONNECT IS E3 RC AT 16
 CONNECT IS E3 RC AT 18
 CONNECT IS E1 RC AT 19
 CONNECT IS E1 RC AT 20
 CONNECT IS E3 RC AT 23
 CONNECT IS E1 RC AT 25
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 59
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS M6 C AT 59

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

L6 0 SEA FILE=CASREACT SSS FUL L4 (0 REACTIONS)

100.0% DONE 385 VERIFIED


0 HIT RXNS

0 DOCS

SEARCH TIME: 00.00.01

=> d.que.stat:124

L7 STR




VAR G1=32/38/26/50

REP G2=(0-10) C
 VAR G3=53/HY
 NODE ATTRIBUTES:
 CONNECT IS E3 RC AT 2
 CONNECT IS E3 RC AT 3
 CONNECT IS E3 RC AT 4
 CONNECT IS E3 RC AT 6
 CONNECT IS E2 RC AT 7
 CONNECT IS E3 RC AT 8
 CONNECT IS E2 RC AT 9
 CONNECT IS E1 RC AT 10
 CONNECT IS E1 RC AT 11
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 45

STEREO ATTRIBUTES: NONE
 L14 STR



VAR G1=32/38/26/50
 REP G2=(0-10) C
 VAR G3=53/HY
 NODE ATTRIBUTES:
 CONNECT IS E3 RC AT 14
 CONNECT IS E3 RC AT 15
 CONNECT IS E3 RC AT 16
 CONNECT IS E3 RC AT 18
 CONNECT IS E1 RC AT 19
 CONNECT IS E1 RC AT 20
 CONNECT IS E3 RC AT 23
 CONNECT IS E1 RC AT 25
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 46

STEREO ATTRIBUTES: NONE

L16 89 SEA FILE=REGISTRY SSS FUL L7
L18 27 SEA FILE=REGISTRY SSS FUL L14
L19 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND L18
L21 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 (L) RACT+ALL/RL
L22 21 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 (L) PREP+ALL/RL
L23 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L21 AND L22
L24 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L19 OR L23

=> d-l24 ibib abs hitstr 1-3

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L24 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:739974 HCAPLUS

DOCUMENT NUMBER: 141:243230

TITLE: A2B adenosine receptor antagonists

INVENTOR(S): Elzein, Elfatih; Kalla, Rao; Marquart, Tim; Zablocki, Jeff; Li, Xiaofen

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 431,167.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004176399	A1	20040909	US 2003-719102	20031121
US 2003139428	A1	20030724	US 2002-290921	20021108
US 6825349	B2	20041130		
US 2003229106	A1	20031211	US 2003-431167	20030506
WO 2005051951	A1	20050609	WO 2004-US38136	20041115

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.:
US 2001-348222P P 20011109
US 2002-401408P P 20020805
US 2002-290921 A2 20021108
US 2003-431167 A2 20030506
US 2003-719102 A 20031121

OTHER SOURCE(S): MARPAT 141:243230

GI



I



II

AB Disclosed are processes for the synthesis of novel compds., I (R1, R2 = optionally substituted alkyl; X = optionally substituted arylene or heteroarylene; Y= covalent bond or lower alkylene; X = optionally substituted monocyclic aryl or heteroaryl), that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea. Thus, amino-N-ethylamide and Et cyanoacetate were reacted in an ethanolic solution of sodium ethoxide to form 6-amino-1-ethyl-1,3-dihydropyrimidine-2,4-dione which was treated with N,N-dimethylformamide dimethylacetal to provide the corresponding azavinyl derivative. The azavinyl derivative was alkylated with Pr iodide and then reduced

to the amine in a solution of aqueous ammonia. The resulting amine was converted to the nitroso using sodium nitrite, and the resulting nitroso was subsequently reduced to the amine using 10% Pd/C. The diamine obtained in the previous step was treated with 1-[[[3-(trifluoromethyl)phenyl]methyl]-pyrazole-4-carboxylic acid and then condensed using NaOH in methanol to give II.


IT 752222-83-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of A2B adenosine receptor antagonists for the treatment of diseases such as asthma and diarrhea)

RN 752222-83-6 HCAPLUS

CN 1H-Purine-2,6-dione, 3-ethyl-3,7-dihydro-1-propyl-8-[1-[[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]]- (9CI) (CA INDEX NAME)



IT 752222-82-5P 752222-84-7P 752222-85-8P

752222-86-9P 752222-87-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)

(preparation of A2B adenosine receptor antagonists for the treatment of diseases such as asthma and diarrhea)


RN 752222-82-5 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(6-amino-1-ethyl-1,2,3,4-tetrahydro-2,4-dioxo-3-propyl-5-pyrimidinyl)-1-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 752222-84-7 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(4-amino-1,2,3,6-tetrahydro-2,6-dioxo-1-propyl-5-pyrimidinyl)-1-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 752222-85-8 HCAPLUS


CN 1H-Pyrazole-4-carboxamide, N-(6-amino-1-ethyl-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)-1-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 752222-86-9 HCAPLUS


CN 1H-Pyrazole-4-carboxamide, N-[4-amino-1-(cyclopropylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-5-pyrimidinyl]-1-[[3-(trifluoromethyl)phenyl]methyl]-

(9CI) (CA INDEX NAME)



RN 752222-87-0 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(6-amino-1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-5-pyrimidinyl)-1-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L24 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:161119 HCAPLUS

DOCUMENT NUMBER: 132:203174

TITLE: Inhibitors of p38- α kinase, preparation thereof, and therapeutic use

INVENTOR(S): Goehring, R. Richard; Luedtke, Gregory R.; Mavunkel, Babu J.; Chakravarty, Sarvajit; Dugar, Sundeep; Schreiner, George F.; Liu, David Y.; Lewicki, John A.

PATENT ASSIGNEE(S): Scios Inc., USA

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012074	A2	20000309	WO 1999-US19845	19990827
WO 2000012074	A3	20000831		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, EE, GE, HU, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2342251	AA	20000309	CA 1999-2342251	19990827
AU 9957936	A1	20000321	AU 1999-57936	19990827
AU 772477	B2	20040429		
EP 1107758	A2	20010620	EP 1999-945316	19990827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9913654	A	20011127	BR 1999-13654	19990827
JP 2002523448	T2	20020730	JP 2000-567192	19990827
PRIORITY APPLN. INFO.:			US 1998-98219P	P 19980828
			US 1999-125343P	P 19990319
			WO 1999-US19845	W 19990827

OTHER SOURCE(S): MARPAT 132:203174
GI



AB Methods are provided for treating conditions mediated by p38- α kinase using compds. I (Z = N, CR1; R1 = noninterfering substituent; X1, X2 = linker; Ar1, Ar2 = (un)substituted C1-20 hydrocarbonyl (at least one of Ar1 and Ar2 = (un)substituted aryl), with proviso that when X2 = CH2 or an isostere thereof, X1 = CO or an isostere thereof, and Ar2 = (un)substituted Ph, Ar1 is other than (un)substituted indolyl, benzimidazolyl or benzotriazolyl, and wherein (un)substituted Ph is not (un)substituted indolyl, benzimidazolyl, or benzotriazolyl; Y = noninterfering substituent; n, m = 0-4; l = 0-3) or a pharmaceutically acceptable salt or pharmaceutical composition thereof. Preparation of compds.

is

described. Compds. of the invention may be used to treat p38- α kinase-mediated conditions.

IT 260427-51-8 260427-52-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(p38- α kinase inhibitors, preparation, and therapeutic use)

RN 260427-51-8 HCAPLUS


CN Pyrazinecarboxamide, N-(6-amino-1,2,3,4-tetrahydro-2,4-dioxo-1,3-dipropyl-5-pyrimidinyl)-3-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]- (9CI) (CA

INDEX NAME)



RN 260427-52-9 HCAPLUS

CN Piperidine, 4-(phenylmethyl)-1-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzoyl]- (9CI) (CA INDEX NAME)



L24 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:736230 HCAPLUS

DOCUMENT NUMBER: 131:337033

TITLE: Immunosuppressive effects of 8-substituted xanthine derivatives

INVENTOR(S): Waer, Mark Jozef Albert; Herdewijn, Piet Andre Maurits Maria; Pfleiderer, Wolfgang

PATENT ASSIGNEE(S): K.U. Leuven Research and Development, Belg.

SOURCE: Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 956855	A1	19991117	EP 1998-201323	19980424
EP 956855	B1	20030312		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

AT 234099 E 20030315 AT 1998-201323 19980424
 ES 2189079 T3 20030701 ES 1998-201323 19980424
 PRIORITY APPLN. INFO.: EP 1998-201323 A 19980424
 OTHER SOURCE(S): MARPAT 131:337033
 GI



AB The title compds. [I; R1-R3 = H, (un)saturated alkyl; X, Y = O, S; Z1 = thienyl, furanyl, cyclopentyl, etc.; Z2 = Ph, sulfonic acid; (un)substituted sulfonamide, etc.], useful for the treatment of auto-immuno disorders, were prepared Thus, alkylation of xanthine I [R1 = H; R2 = R3 = Me; Z1 = H; X = Y = O] with propargyl bromide afforded I [R1 = HC.tplbond.CCH2; R2 = R3 = Me; Z1 = H; X = Y = O] which showed IC50 of > 200 μ M in vitro MLR experiment


IT 93214-88-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(immunosuppressive effects of 8-substituted xanthine derivs.)

RN 93214-88-1 HCAPLUS

CN 1H-Purine-2,6-dione, 8-[1,1'-biphenyl]-4-yl-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)



IT 249929-74-6P 249929-83-7P 249929-84-8P


RL: RCT (Reactant); SPN (Synthetic preparation);

PREP (Preparation); RACT (Reactant or reagent)

(immunosuppressive effects of 8-substituted xanthine derivs.)


RN 249929-74-6 HCAPLUS

CN 1H-Purine-2,6-dione, 8-[1,1'-biphenyl]-4-yl-3,7-dihydro-3-propyl- (9CI) (CA INDEX NAME)




RN 249929-83-7 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-(6-amino-1,2,3,4-tetrahydro-2,4-dioxo-1-propyl-5-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 249929-84-8 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-(6-amino-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-5-pyrimidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT